^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

ER (Estrogen receptor)

i
Other names: ESR1, Era, ESR, NR3A1, ER, ER beta
17h
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) (clinicaltrials.gov)
P2, N=120, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
Enrollment closed
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • EGFR negative
|
everolimus • fulvestrant • exemestane • Welireg (belzutifan)
18h
Lymph Node Findings Following Axillary Lymph Node Dissection in Cases of a Positive Sentinel Lymph Node in Breast Cancer. (PubMed, Cureus)
Conclusions In this retrospective, single-center study, 58.8% of patients with a positive SLN had additional axillary metastases following completion ALND, underscoring that residual nodal disease remains common and clinically significant. Conversely, 41.2% had no further axillary involvement, consistent with literature supporting selective de-escalation of axillary surgery in carefully selected patients.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
18h
Investigation of potential targets and mechanisms of naringenin in the treatment of spinal cord injury: A network pharmacology, molecular docking, and molecular dynamics simulation study. (PubMed, Medicine (Baltimore))
The results show that the core targets of NAR for spinal cord injury include estrogen receptor 1, AKT serine/threonine kinase 1, B-cell lymphoma 2, PPARG, MAPK8, mechanistic target of rapamycin, protein kinase cAMP-activated catalytic subunit alpha, and HRas proto-oncogene, GTPase...In summary, this study systematically predicts the key targets and signaling pathways through which NAR may act in SCI, providing a theoretical basis for future mechanistic and translational research. However, because the findings are based on computational analyses alone, further in vitro and in vivo validation is required.
Journal
|
ER (Estrogen receptor) • BCL2 (B-cell CLL/lymphoma 2) • HRAS (Harvey rat sarcoma viral oncogene homolog) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • PRKACA (Protein Kinase CAMP-Activated Catalytic Subunit Alpha) • AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1) • MAPK8 (Mitogen-activated protein kinase 8)
|
sirolimus
18h
Multi-omics investigation of per- and polyfluoroalkyl substances in lung adenocarcinoma: comprehensive network toxicology, machine learning and molecular docking experiments. (PubMed, Mol Divers)
Therefore, this study clarifies how PFAS contribute to the development of LUAD and explores the molecular pathways involved, providing crucial insights into the toxicological effects of PFAS. Furthermore, it establishes a theoretical basis for devising preventive strategies and therapeutic approaches for pulmonary diseases related to PFAS exposure.
Journal
|
EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
18h
CBCRisk-Mastectomy: A Prediction Tool to Aid Contralateral Prophylactic Mastectomy Decision- making. (PubMed, J Surg Res)
CBCRisk-Mastectomy may aid clinicians in counseling BC patients scheduled for mastectomy, enabling improved decision-making regarding CPM.
Journal
|
ER (Estrogen receptor)
18h
Spatial analyses implicate high stromal tumour-infiltrating CD8+ lymphocytes as a negative predictive marker for chemotherapy in estrogen receptor-positive breast cancer. (PubMed, Nat Commun)
In our randomised, Intermediate RS cohort treated with chemotherapy we observe an association between higher stromal tumour-infiltrating CD8+ lymphocyte (sTIL CD8+) density and poor outcome (ΔLR-χ2: 6.79, p = 0.009), which we validate using data from whole-resection specimens (ΔLR-χ2: 8.90, p = 0.003). Our data thus provide insights into the immune states in ER+HER2- breast cancer, and propose sTIL CD8+ density as candidate biomarker for treatment decisions.
Journal • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CD8 (cluster of differentiation 8) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CD96 (CD96 Molecule)
|
ER positive • HER-2 negative
|
Oncotype DX Breast Recurrence Score®Test
18h
Oestrogen receptor phosphorylation profiles and in silico PAM50 subtyping reflect sexual dimorphism in breast cancer. (PubMed, J Pathol Clin Res)
We show that male BC does not align with female BC in the same way that intrinsic subtypes of female BC are not identical. As BC heterogeneity is well recognised, we propose that male BC should be considered as a potentially unique clinical subtype of BC.
Journal
|
ER (Estrogen receptor)
|
Prosigna® Breast Risk of Recurrence (ROR) Test
19h
Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer (clinicaltrials.gov)
P2, N=27, Recruiting, Xijing Hospital | Trial primary completion date: Apr 2026 --> Dec 2026
Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
|
Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • cyclophosphamide • epirubicin
19h
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer (clinicaltrials.gov)
P2, N=40, Recruiting, University of Illinois at Chicago | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • ER positive • HER-2 negative • HER-2 negative + ER positive
|
MammaPrint® • EndoPredict®
|
azacitidine
1d
The PER2:BRCA1:POU2F1(OCT-1) ternary complex represents a multi-component scaffold model for circadian gene regulation. (PubMed, Neurobiol Sleep Circadian Rhythms)
Circadian transcriptome analysis revealed that Esr1 exhibits robust clock-dependent oscillations that are abolished in Per1/2 double-knockout mice, while Pou2f1 and Brca1 maintain constitutive expression. These findings establish PER2 as a circadian scaffold that assembles multivalent protein complexes to temporally gate transcription, providing mechanistic insight into how circadian disruption can influence target gene expression.
Journal • BRCA Biomarker
|
ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset) • PER2 (Period Circadian Regulator 2) • PER1 (Period Circadian Clock 1)
1d
Enrollment closed • First-in-human
|
PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset)
|
PD-L1 expression • HER-2 positive • HER-2 amplification • HER-2 expression • BRCA mutation • PD-L1 expression + HER-2 overexpression
|
Herceptin (trastuzumab) • paclitaxel • IPH5301
1d
Unmasking the Myositis: A Diagnostic Clue to Occult Breast Cancer. (PubMed, Cureus)
Despite the initiation of corticosteroids and methotrexate, the patient showed clinical deterioration over four weeks...Following neoadjuvant chemotherapy, surgery, and radiation, the patient achieved complete remission of her myositis, with normalisation of creatine phosphokinase (CPK) levels, resolution of rash, and recovery of muscle strength, confirming the paraneoplastic aetiology. This case underscores the imperative to pursue malignancy screening in DM patients unresponsive to immunosuppressive therapy, regardless of age. It highlights the critical role of thorough physical examination and the superiority of breast imaging in young women with dense breasts.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • PGR positive
|
methotrexate